SUMMARY. Adenosine is known to cause atrioventricular block by slowing conduction through the atrioventricular node, thereby lengthening the atria to His (A-H) interval. To test the hypothesis that the increase in atrioventricular conduction delay produced by adenosine is mediated at an extracellular site, the efficacy of nucleoside transport inhibitors in preventing cellular adenosine uptake was correlated with their ability to potentiate the atrioventricular block and prolong the A-H interval. The antagonism of aminophylline and adenosine also was examined. Since methylxanthines are known to inhibit cyclic nucleotide phosphodiesterase, to release catecholamines from nerve terminals, and to block adenosine receptors, it was determined whether the ability of aminophylline to reverse the adenosine-induced prolongation of the atrial-His interval and atrioventricular block was associated with an increase in myocardial cyclic AMP and/or release of norepinephrine. The atrial-His conduction time and adenosine uptake and release were determined in isolated perfused guinea pig and rat hearts. The nucleoside transport inhibitors dipyridamole, nitrobenzylthioinosine, and diazepam caused a dose-dependent decrease in the uptake of 14 Cadenosine. Nitrobenzylthioinosine was the most and diazepam the least effective in blocking adenosine uptake. Dipyridamole (5 X 10~6 M) inhibited uptake by 97% and increased adenosine levels in the perfusate. These effects were strongly correlated with a potentiation of adenosineinduced atrial-His prolongation (r = 0.99). The oligonucleotide, adenyl (3'-5')9-adenosine, an agent restricted to the extracellular space as a result of its large molecular size, was found to be 1.8 times more potent per mole than free adenosine. 2'-Deoxyadenosine and N 6 -methyladenosine, respectively, were found to have either no effect or an effect similar to that of free adenosine on the atrial-His interval. Aminophylline (1 X 1CT 5 to 3 X 10~5 M) in the presence or absence of propranolol antagonized in a dose-dependent and competitive manner the prolongation of the atrial-His interval and atrioventricular block caused by adenosine. In concentrations up to 10~4 M, aminophylline did not cause any accumulation of myocardial cyclic AMP, nor did it increase the release of norepinephrine. We conclude (1) that the effect of adenosine on atrioventricular conduction results from binding to an extracellular receptor that resembles the R site described for other actions of adenosine in different tissues, and (2) that the reversal of adenosine-induced increases in atrioventricular conduction delay by aminophylline is not due to phosphodiesterase inhibition and/or release of norepinephrine from nerve terminals. (Circ Res 51 -.569-579, 1982) 
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-methyladenosine, respectively, were found to have either no effect or an effect similar to that of free adenosine on the atrial-His interval. Aminophylline (1 X 1CT 5 to 3 X 10~5 M) in the presence or absence of propranolol antagonized in a dose-dependent and competitive manner the prolongation of the atrial-His interval and atrioventricular block caused by adenosine. In concentrations up to 10~4 M, aminophylline did not cause any accumulation of myocardial cyclic AMP, nor did it increase the release of norepinephrine. We conclude (1) that the effect of adenosine on atrioventricular conduction results from binding to an extracellular receptor that resembles the R site described for other actions of adenosine in different tissues, and (2) that the reversal of adenosine-induced increases in atrioventricular conduction delay by aminophylline is not due to phosphodiesterase inhibition and/or release of norepinephrine from nerve terminals. (Circ Res 51 -.569-579, 1982) ADENOSINE is thought to act in the heart as a regulator of coronary blood flow and as an attenuator of the myocardial effects of catecholamines (Berne, 1963; Gerlach et al., 1963; Schrader et al., 1977a) . We also presented evidence that adenosine may play a role as a biochemical mediator of the atrioventricular (AV) conduction disturbances observed when myocardial oxygen availability is limited (Belardinelli et al., 1980 (Belardinelli et al., ,1981 . The modulatory role exerted by adenosine appears to involve specific receptor sites localized on the surface of the cellular membrane (Olsson et al., 1976; Schrader et al., 1977b) . In addition, all of the above-mentioned actions of adenosine have been found to be antagonized by methylxanthines in micromolar concentrations (Fredholm, 1980; Rail, 1981) .
For example, the AV conduction delay and block caused by adenosine was antagonized by aminophylline, whereas the same degree of AV conduction impairment produced by either acetylcholine or MnCl2 could not be reversed by aminophylline (Belardinelli et al., 1980) . Hence, it was suggested that the aminophylline reversal of adenosine's action in the AV node was selective, and most likely due to displacement of adenosine from its receptor site on the outer surface of the membrane (Belardinelli et al., 1980 (Belardinelli et al., , 1981 .
Two processes modulate the concentration of extracellular adenosine. One process involves the release of adenosine by the cells, and the second, its removal from the extracellular space by transport into the cell with subsequent metabolism. Perturbation of either process will alter the steady state extracellular concentration of adenosine. For example, inhibition of adenosine uptake would be expected to increase its concentration in the extracellular space, hence potentiate its effects, particularly if there is binding to a specific receptor site on the external surface of the membrane. In fact, many of adenosine's actions have been shown to be augmented by nucleoside transport inhibitors (Hopkins, 1973; Kolassa et al., 1971; Hartzell, 1979 ).
The present investigation was undertaken to test the hypothesis that the previously reported adenosine-induced prolongation of AV conduction is mediated at an extracellular site. This was accomplished by: (1) comparing the efficacy of several inhibitors of nucleoside transport in preventing cellular adenosine uptake with their ability to potentiate the AV conduction delay caused by adenosine, and (2) examining the effects of an adenosine polymer too large to permeate the cell membrane and two other adenosine analogs previously suggested to specifically activate internal or external adenosine receptors. Furthermore, we set out to determine whether aminophylline reversal of the adenosine-induced increase in AV conduction delay is associated with the ability of aminophylline to stimulate the release of catecholamines and/or increase myocardial cyclic AMP.
Methods
Isolated guinea pig and rat hearts were perfused at a constant flow of 4 to 5 ml/min per g with a modified KrebsHenseleit solution oxygenated with 95% Oz-5% CO2 as previously described (Belardinelli et al., 1980) . The sinoatrial node region was excised and the right atrium was opened to expose the AV node region. The hearts were placed in a bath filled with Krebs-Henseleit solution. The bath and myocardial temperatures were continuously monitored (YSI probes 421 and 524, respectively) and maintained at 35° ± 1°C. The hearts were perfused at 35°C in order to provide more stable preparations and to facilitate pacing. In a separate series of experiments designed to test whether lower temperature influences myocardial adenosine uptake, the hearts were perfused at 32°C. The hearts were electrically paced at cycle lengths between 170 and 600 msec with a pair of Teflon-coated, steel wires placed on the surface of the left atrium. A Grass model S-88 stimulator provided the stimuli via a stimulus isolation unit as rectangular wave pulses of 2-3 msec duration and twice threshold intensity.
Electrodes were appropriately placed to permit recording of the left atrial and His-bundle electrogram according to techniques previously described (Belardinelli et al., 1980) . The recorded signals showed the stimulus artifact, the left atrial (A), the His-bundle (H) and the ventricular (V) depolarizations. From these signals, the following AV conduction times were measured: (1) cycle length, defined as the interstimulus interval, (2) A-H interval, which represents the conduction time from the atrial tissue to the bundle of His, and (3) H-V interval, which represents the conduction time from the bundle of His to the ventricular myocardium. All these measurements are expressed in milliseconds.
Adenosine (Sigma), aminophylline (Invenex), propranolol (Sigma) dipyridamole (DPM, gift from Boehringer Ingelheim), diazepam (DIAZ, Hoffman-La Roche), and nitrobenzylthioinosine (NBMPR, gift of Dr. Alan R.P. Paterson, Edmonton, Canada) were dissolved in perfusion medium and infused to achieve the desired perfusion fluid concentrations. To ensure complete mixing, all agents were introduced into the perfusion line via a T-connection proximal to the peristaltic pump.
Uptake of

14
C-Adenosine
Guinea pig and rat hearts were prepared for isolated perfusion as described above. After a 15-minute equilibration period, perfusion was initiated with physiological saline solution (PSS) containing [U-14 C]adenosine (0.3 Ci/ml; Amersham) in combination with [6,6'(n)-3 H] sucrose (3 Ci/ml; Amersham) for extracellular space (ECS) determination. Unlabeled adenosine was present in a concentration of 10~7 M. At the termination of the 20-minute uptake period, the ventricles were removed, minced fine, and digested in Protosol (New England Nuclear). Heart digests and aliquots of perfusates were then mixed with ReadySolv EP (Beckman) and counted, using standard liquid scintillation techniques. Adenosine uptake values were corrected for ECS contamination. The mean ECS values for all experiments were 0.4066 ± 0.254 and 0.4949 ± 0.0360 (SEM) ml/g for guinea pigs and rats, respectively. All uptake values are presented as nanomoles of adenosine per g wet weight.
Dipyridamole and Perfusate Adenosine
In this series of experiments (n = 7), the isolated hearts were prepared as described above. After 30 minutes of equilibration, control samples of the effluent were collected from each heart. Adenosine was infused to achieve a final concentration of 5 X 10" b M. After 5 minutes, an effluent sample was obtained. Twenty minutes after stopping the infusion of adenosine, we collected another effluent sample (post-ADO control sample). At this point, the infusion of dipyridamole was initiated to achieve a concentration of 5 X 10~6 M. At 10 minutes, the simultaneous administration of adenosine was resumed. After 5 minutes of adenosine infusion, an effluent sample was again collected. At the end of the experiment, a perfusate sample was obtained to verify the concentration of the exogenous adenosine.
Electrophysiological Studies: Protocols
General
Once the stimulating and recording electrodes were securely placed, we allowed 30 minutes before starting control measurements. All experimental interventions were preceded and followed by control measurements. Whenever the total AV conduction time in the pre-and post-control periods differed by more than 15%, the intervening experimental data were discarded. The AV conduction times all were determined at cycle lengths of 500 msec, as well as at other cycle lengths between 150 and 650 msec.
Potentiation of Adenosine Effect by Nucleoside Transport Blockers
After control determinations of AV conduction times, adenosine was infused for a period of at least 5 minutes and new recordings were obtained. The infusion of adenosine was interrupted and, at 10 minutes, post-ADO control records were obtained. At this point, the infusion of one of the nucleoside transport inhibitors was initiated. After 10 minutes, AV conduction times were again determined. With the continued infusion of nucleoside transport inhibitors, simultaneous administration of adenosine was initiated at the same final perfusate concentration as in the first infusion. Recordings were obtained after 5 minutes. Finally, the adenosine infusion was stopped and post-ADO control measurements in the presence of the nucleoside transport inhibitor alone were obtained. Such a protocol allowed comparison between the effects of adenosine and nucleoside transport inhibitors, alone, as well as in combination. The experimental protocol can be summarized as follows: control (C-l); adenosine (ADO); adenosine washout (C-2), nucleoside transport inhibitor (NTI), NTI + ADO and NTI (i.e., ADO washout). The above steps were carried out consecutively. Figures 3 and 5 are labeled accordingly. The nucleoside transport inhibitors used were: dipyridamole (DPM); nitrobenzylthioinosine (NBMPR), diazepam (DIAZ).
Adenosine Analogs
Further characterization of the adenosine site of action was obtained by measuring AV conduction times with the adenosine analogs, adenyl-(3'-5')c,-adenosine [(Ap)g-adenosine, (Boehringer-Mannheim] , N 6 -methyladenosine and 2'-deoxyadenosine (Sigma). Solutions of all compounds were made up fresh before each experiment. The studies with analogs followed similar protocols, as did the experiments with adenosine.
Antagonism between Aminophylline and Adenosine
The dose-response curve for adenosine was obtained by infusing progressively increasing doses of adenosine, with the measured parameters allowed to return to control levels before infusion of each subsequent dose. The infusions of adenosine then were repeated in the same heart during perfusion with aminophylline.
In a separate series of experiments, effluent samples from the hearts were collected and analyzed for norepinephrine content. Thirty minutes after secure placement of the electrodes for stimulation and recording, the electrophysiological parameters of the hearts were recorded and control samples of the effluent perfusate were collected. In one group of hearts, aminophylline was infused to achieve various perfusate concentrations between 3 X 1CT 5 M and 10~2 M. After 5 minutes of infusion, new measurements were made and effluent perfusate samples were collected. The hearts then were frozen rapidly between aluminum blocks precooled in liquid nitrogen. Myocardial adenosine and cyclic AMP levels were subsequently determined. In a second group of hearts, after control measurements and effluent perfusate sampling, adenosine was infused to achieve a constant perfusate concentration of 5 X 10~6 M. After 5 minutes of infusion, the electrophysiological parameters were recorded and effluent perfusate samples were obtained. With continued adenosine infusion, aminophylline was infused to achieve specific concentrations of this drug. The hearts then were frozen and processed as in the previous group.
Analytical Procedures
Effluent Samples
1. Adenosine. The adenosine concentration in the effluent of the isolated perfused guinea pig hearts were measured as follows. Samples of 7 ml of the effluent were collected in tubes containing 1 ml of ice-cold 0.5 N perchloric acid. The samples were neutralized (pH 7.0) with KOH and centrifuged for 10 minutes at 3,000 rpm. The supernatant fraction was collected and assayed for adenosine using reverse phase high-performance liquid chromatography in a manner similar to that employed by Hastwick et al. (1979) . Briefly, the sample was passed through an Altex Ultrasphere ODS(SM) (Beckman) using a 4 mix KH 2 PO< buffer (pH = 4.6) with 5% methanol (vol/vol). The adenosine was detected by a model 440 absorbance detector at 254 jum.
2. Norepinephrine. Samples of 7 ml of the effluent perfusate were collected in tubes containing 200 fil of ice-cold catecholamine standard (4 X 10" 8 M of norepinephrine, epinephrine, and dopamine) and immediately stirred and frozen at -20°C. Catecholamines were adsorbed on acidwashed alumina at pH 8.6. The adsorbed catecholamines were eluted from the alumina with 250 jil of 0.05 N perchloric acid. The samples then were analyzed for catecholamines by injecting a 200-fil aliquot into a Biophase ODS 5 micron reverse phase column coupled to a Bioanalytical Systems high performance liquid chromatograph with an electrochemical detector. The lower limit of detection for norepinephrine was 50 pg/200-/il sample, and the overall average recovery was 60%.
Tissue Samples
The frozen ventricles were ground to a fine powder and homogenized in ice-cold 0.5 N perchloric acid with a polytron tissue disruptor. Following centrifugation, the supernatant fraction was separated from the pellet and analyzed for cyclic AMP as described below. The pellet was dissolved in a heated (37°C) solution of 2 N NAOH, and analyzed for protein by an autoanalyzer technique adapted to the method of Lowry et al. (1951) .
1. Cyclic AMP. The supernatant fraction was neutralized and acetylated by the addition of 40 microliters of a 3/1 (vol/vol) mixture of triethylamine and acetic anhydride. The samples were then assayed for cyclic AMP by an automated radioimmunoassay system (Brooker et al., 1976) against standards prepared in 50% saline-50% 0.2 N HO.
Data Analysis
Statistical analysis was based on the Student's r-distribution for paired (intervention vs. average pre-and postcontrol) data, except for the uptake data, which were tested in a manner similar to that used for unpaired data. Linear regression analysis was used to determine the correlation between adenosine uptake and prolongation of the A-H interval. Significance was considered for P < 0.05.
Results
Uptake of 14 C-Adenosine
The adenosine uptake in isolated perfused guinea pig (n = 15) and rat (n = 7) hearts was 2.19 ± 0.18 nmol/g wet wt and 2.15 ± .19 nmol/g wet wt, respectively (mean ± SEM). Each of the nucleoside transport blockers tested inhibited the uptake of adenosine (Fig.  1) . NBMPR was the most, and DIAZ the least effective in blocking adenosine uptake. Decreasing the myocardial temperature to 32°C also caused a 21% decrease in the uptake of adenosine (Fig. 1 ). DPM at 5 X 10~8 M inhibited the adenosine uptake by 49%, whereas, at 5 X 1CT 6 M, a 97% decrease in uptake was observed ( Fig. 1) . Adenosine uptake did not vary with tachycardia (pacing at 2 and 3 Hz), not shown.
As depicted in Figure 2 , DPM was less efficacious in inhibiting the uptake of adenosine in the rat heart than in the guinea pig heart. At 5 X 10~8 M, DPM failed to inhibit adenosine uptake. Increasing the dose of DPM to 5 X 10" 6 M caused a 35% reduction in adenosine uptake in rats, whereas the same concentration of DPM in guinea pig hearts resulted in a 97% decrease in adenosine uptake.
Influence of Dipyridamole on the Extracellular Concentration of Adenosine
In seven guinea pig hearts, the basal effluent concentration of adenosine was 7.47 X 10~9 M. Exogenous adenosine then was infused to achieve a perfusate concentration of 4.66 X 10~6 to 5.06 X 10~6 M. AS can be seen in Table 1 , when adenosine was infused into the hearts, less than half of the infused nucleoside was recovered in the effluent. However, when the preparation was pretreated with 5 X 1CT 6 M DPM, a concentration known to inhibit 97% of the adenosine uptake ( Fig. 1) , the amount of adenosine recovered in the effluent was similar to the amount of adenosine infused.
Effects of Adenosine and Nucleoside Transport Inhibitors on AV Conduction
Adenosine-induced prolongation of the AV conduction time was observed with each of the nucleoside transport blockers (Figs. 3 and 4) . The increase in AV conduction time was due to the prolongation of the A-H interval, whereas the H-V interval remained unaltered for each preparation and was in the range of 10-16 msec. Figure 4 illustrates the effect of adenosine at two different doses of DPM. Adenosine alone (3 X 10" 7 M), as well as DPM alone (either 5 X 10~8 or 5 X 10" 6 M), did not cause a significant increase in the A-H interval at any of the cycle lengths examined. However, when DPM was combined with adenosine, a marked prolongation of the A-H interval was observed. Similarly, when DPM and adenosine were combined, AV block (Wenckebach) occurred at a lower rate of pacing, as indicated by the shift of X to the right. Thus, the A-H vs. cycle length relationship was displaced upward and to the right in the presence of DPM plus adenosine.
As depicted in Figure 2 , 5 X 10" 8 M DPM failed to inhibit significantly the uptake of H C-adenosine in rat hearts. Consonant with these findings, in rat hearts, 3 X 10~7 M adenosine did not prolong the A-H interval in the presence of 5 X 10~8 M DPM, whereas, in guinea pig hearts, DPM had a significant effect on the recorded response to adenosine (Fig. 5) .
The efficacy of nucleoside transport inhibitors in blocking adenosine uptake was correlated with their ability to enhance the adenosine-induced A-H prolongation. As can be seen in Figure 6 , irrespective of the nucleoside transport blocker used, a significant correlation (r = 0.99) between adenosine uptake and the A-H increments was observed; that is, the greater the inhibition of adenosine uptake, the greater was the adenosine-induced A-H prolongation. The correlation also held true for different doses of blockers. For example, the adenosine-induced A-H prolongation was greater at 5 X 10~6 M DPM than at 5 X 10~8
In order to compare the influence of the concentration of adenosine on the ability of DPM to influence the response to adenosine, we performed four additional experiments with guinea pig hearts. The experiments were conducted as before except that the results obtained were compared with different concentrations of adenosine (2 X 10~8 M and 3 X 10~7 M) at same dose of DPM (5 X 10~8 M). The influence of DPM on the adenosine-induced A-H prolongation was assessed by the difference of effect between dipyridamole plus adenosine and adenosine alone. The A-H increment (msec) caused by the combination of adenosine (2 X 10~8 M) and dipyridamole (5 X 10~8 M) was 3 ± 0.5 msec, whereas 3 X 10~7 M adenosine in combination with 5 X 10~8 M dipyridamole resulted in an A-H increment of 9 ± 1 msec. Thus, the effect of adenosine in the presence of DPM was enhanced by increasing the adenosine concentration. Table 2 summarizes the effect of adenosine and adenyl (3'-5') 9 -adenosine on the A-H interval of seven hearts. The response of the AV node to (AP)9-adenosine was 1.8 times greater than the response produced by free adenosine. The H-V interval in this series was 12 ± 2 msec and was not affected by either adenosine or (AP)g-adenosine (not shown).
Effects of Adenosine Analogs on AV Conduction
To help differentiate between the relative impor- tance of P and R receptor sites for adenosine, three additional experiments examining the effects of the adenosine analogs 2'-deoxyadenosine and N 6 -methyladenosine were conducted. The analog 2'-deoxyadenosine in concentrations up to 2 X 10~5 M did not cause any prolongation of the AV conduction times. Furthermore, 2'-deoxyadenosine plus DPM also failed to cause any effect on AV conduction. In contrast, 2 X 10~5 M N 6 -methyladenosine produced a 31 ± 4 msec prolongation of the A-H interval without affecting the H-V interval at a pacing rate of 2.5 Hz. Like' adenosine, the effects of N 6 -methyladenosine on the AV conduction were enhanced significantly by DPM.
Effects of Aminophylline on Adenosine-Induced Changes in AV Conduction
The adenosine-induced prolongation of AV conduction time is due to the lengthening of the A-H interval without changing the H-V interval. This is 
FIGURE 5. Effects of adenosine (ADO, 3 X 1O' 7 M) and dipyridamole (DPM, 5 X 10~s M) on the A-H interval in isolated rat and guinea pig hearts. The depicted data were obtained sequentially, left to right, at a pacing rate of 2.5 Hz and represent the mean ± SEM from five rats and seven guinea pig hearts. C-l and C-2 are control and ADO washout, respectively. Note that, in the guinea pig, but not in the rat, the values obtained with DPM plus ADO were significantly higher than those with ADO alone (P < 0.05).
illustrated in Figure 7 , tracing B, where the A-H interval was increased to 68 msec, 4 minutes after infusion of 7 X 10~6 M adenosine was begun. The H-V interval remained unchanged at 12 msec. Three minutes after the initiation of an aminophylline (3 X 10~5 M) infusion (tracing C), in the continued presence of adenosine, the prolongation of the AV conduction time was eliminated and the A-H interval returned to the control value of 35 msec (tracing C). This pattern was generally observed, as indicated in Figure 8 . The adenosine-induced A-H prolongation was found to be dose-dependent, and it was significant at concentrations above 7 X 10~7 M. Adenosine at concentra- 
Correlation between the degree of adenosine uptake and the observed change in the A-H interval in isolated guinea pig hearts. The A-H increments were obtained by subtracting the A-H (msec) interval values obtained with adenosine plus nucleoside transport blockers from those obtained with adenosine alone. The correlation is significant, irrespective of the nucleoside blocker used and its concentration.
Effects of Adenosine and Adenyl (3'-5')9-Adenosine on the A-H Interval of Guinea Pig Hearts
Rate (Hz) Control Adenosine (1.5 X lCT" M) (AP)9-A (1.5 X 10" 6 M) 35 ± 0.5 39 ± 0.5 44 ± 2.0 38 ± 1 44 ± 2 50 ± 2 41 ± 1* 47 ± 2 55 ± 3* A-H(msec) mean + SEM, adenosine and (AP) 9 -A significantly (P < 0.05) prolonged the A-H interval at all rates.
* Statistically different (P < 0.05) from adenosine.
tions above 7 X 10~6 M caused second-and thirddegree heart block. Aminophylline in a dose-dependent manner antagonized the adenosine-induced A-H prolongation and AV block. Note that 3 X 10" 5 M aminophylline (closed triangles, Fig. 8 ) completely reversed the A-H prolongation caused by 5 X 1CT 6 M adenosine. The same data are plotted on a double reciprocal (Lineweaver-Burke) plot in Figure 9 . The lines obtained in control and at different concentrations of aminophylline intersect the Y-axis at 0.05 msec" 1 , equivalent to a 20-msec increase in A-H interval. These data suggest that aminophylline antagonizes the response to adenosine by a mechanism of competitive inhibition. Aminophylline (10~5 M) by itself had no significant effect on AV conduction. The mean pre-and post-aminophylline A-H interval was 34.5 ± .5 msec, and 3 minutes after the infusion of 10~5 M aminophylline, was 34 ± 1 msec.
The reversal of the adenosine-induced A-H interval by aminophylline was also studied in hearts treated with 10~6 M propranolol. Propranolol (10~6 M) by itself had no effect on the A-H conduction time and did not influence the heart's response to adenosine. In addition, the reversal of the adenosine-induced A-H prolongation and AV block by 3 X 10~5 M aminophylline was not affected by 10~6 M propranolol. 
. Typical His-bundle electrogram showing the reversal of adenosine (ADO)-induced A-H prolongation by aminophylline (AM1NO). Tracing A: Control. Tracing B: 7 X 10~6 M ADO. Note that the prolongation of A V conduction time is due to the lengthening of the A -H interval without changing the H-V interval. Tracing C: 3 minutes after the administration of 3 X 10''' M AMINO in the continued presence of ADO. S = stimulus artifact. A, H, and V denote atrial, His-bundle and ventricular depolarization, respectively. CL = cycle length in msec. The A-H and H-V subintervals are expressed in msec.
FIGURE 8. Summary of data demonstrating the effect of aminophylline (AMINO) on dose-response curves to adenosine (ADO). Filled circles (0) control dose response curve, i.e., ADO alone (n = 8). Open circles (O) dose response curve after administration of 1 X 10~: > M AMINO (n = 7). Filled triangles (A) dose response curve after administration of 3 X 1CT 5 M AMINO (n = 3). Note that ADO at concentrations above 7 X 10~G M caused AV block and that AMINO reversed this. Each data point represents the mean ± SEM obtained at a pacing rate of 2.5 Hz and at a temperature of36°C.
Release of Norepinephrine and Accumulation of Myocardial Cyclic AMP
These experiments were designed to determine whether the aminophylline reversal of the adenosineinduced increase in AV conduction delay is associated with an increased release of norepinephrine and ac- cumulation of myocardial cyclic AMP. As shown in Figure 10A , aminophylline in concentrations up to 1CT 4 M did not cause any significant increase in the release of norepinephrine. A small but not statistically significant increase in the release of norepinephrine was observed at 1 X 10~4 M, whereas at higher concentrations (1 X lCT 2 M), a significant increase in norepinephrine release occurred. Similar results were observed when aminophylline was administered in combination with 5 X 10" 6 M adenosine (Fig. 10B ). Adenosine alone did not affect the release of norepinephrine. The reversal of 5 X 1CT 6 M adenosineinduced prolongation of A-H with aminophylline at concentrations ranging from 1 X 10~5 to 1 X 10~4 M was not accompanied by an increase in norepinephrine release.
The basal cyclic AMP levels in this series of hearts ranged from 7.23 to 12.9 pmol/mg protein with a mean ± SEM of 9.7 ± 0.58 (Fig. 11A ). Aminophylline (from 3 X 10" 5 up to 1 X 10" 4 M), alone (Fig. 11A ) or in combination with 5 X 10~6 M adenosine (Fig. llB) , did not cause a significant increase in cyclic AMP, whereas, at 1 X 10~2 M, aminophylline caused a significant accumulation of cyclic AMP (Fig. HA) . Adenosine (5 X 10" 6 M) alone did not cause any change in the basal levels of cyclic AMP (Fig. llB) . 
Discussion
It has been suggested that adenosine plays a significant role in physiological processes in various tissues (Berne, 1963; Schrader et al., 1977a; Belardinelli et al., 1980; Trost and Schwabe, 1981) . The effects of adenosine have been assumed to be mediated by specific receptor sites on the external surface of membranes. The conclusion that adenosine must first bind to a specific sarcolemmal receptor has been based on the evidence that (1) the responses to adenosine persist or are enhanced by nucleoside transport inhibitors such as DPM; and (2) impermeable analogs of adenosine cause the same or a greater response than does free adenosine. More direct evidence for adenosine receptors in brain and fat cells is based on the recent binding studies with the radioligand (-)-N 6 -[ 3 H]phenylisopropyIadenosine (Schwabe and Trost, 1980; Trost and Schwabe, 1981) . In heart, Dutta and Mustafa (1979) In recent years, we have obtained evidence that adenosine may play a significant role as a mediator of the AV conduction disturbances accompanying myocardial hypoxia and ischemia (Belardinelli et al., 1980 and . The present findings confirm previous observations (Drury and Szent-Gyorgyi, 1929; Stafford, 1966; Belardinelli et al., 1980 ) that adenosine causes AV node conduction delay and block, and provide evidence that the negative dromotropic effect of adenosine is mediated via an extracellular site of action. The rationale for using nucleoside transport inhibitors to characterize the site of adenosine action is based on the following premises. By blocking adenosine uptake, the concentration of the nucleoside in the extracellular spaces should increase and, thus, increase the amount of adenosine available for binding to an external receptor. Assuming that the adenosine receptor's binding characteristics and the extracellular destruction rate of adenosine would not be affected, the effects of adenosine should be enhanced if indeed they involve binding to specific receptor sites on the external surface of the membrane. It was shown that different nucleoside transport inhibitors were effective in reducing the uptake of 14 C-adenosine and that the effect was dose-dependent. It was also shown that DPM in a concentration that almost totally blocks the uptake of 14 C-adenosine completely prevented the reduction in the levels of perfusate adenosine in a single pass through the heart. Thus, the inhibition of adenosine uptake resulted in an increase in its concentration in the extracellular space. Concomitantly, adenosine prolonged the A-H interval in the presence of DPM. Figure 6 shows that, irrespective of the nucleoside transport inhibitor used or its concentration, the lesser the uptake of adenosine by the heart, the greater was the effect of adenosine. The findings that in the rat, 5 X 10~8 M DPM failed to inhibit adenosine uptake, and similarly did not result in an adenosine-induced A-H prolongation, further support the correlation between adenosine uptake and its effects on AV conduction. The species differences in the effects of DPM on adenosine transport are in agreement with a previous report (Kolassa et al., 1971) .
The cellular transport mechanism of nucleosides appears to be competitive, i.e., adenosine, inosine, and adenosine analogs compete for the same carrier (Kolassa et al., 1970; Plagemann and Richey, 1974; Berlin and Oliver, 1975) . The present observation that, for the same concentration of DPM (5 X 10" 8 M), the adenosine-induced A-H prolongation was three times greater at 3 X 10~7 than at 2 X 10~8 M, indirectly supports the idea of a competitive carrier transport system for nucleosides.
The main conclusions of this study rest on the observed effects of NBMPR, DPM, and DIAZ on adenosine transport. However, DPM may also modify the activity of other membrane transport systems (Berlin and Oliver, 1975 ) and inhibit adenosine deaminase (Deuticke and Gerlach, 1966; Kiibler et al., 1970) , but it is unlikely that these effects are responsible for the results presently reported, since they Bunag et al. (1964) , Deuticke and Gerlach (1966) , and Kiibler et al. (1970) , the inhibition of adenosine deaminase by DPM is weak and requires concentrations that far exceed the concentration necessary to inhibit the uptake of adenosine significantly. However, NBMPR has been reported to be a very specific inhibitor of nucleoside transport (Paterson, 1979) . According to some investigators (Schiitz et al., 1981) , but not others (Mustafa, 1979) , NBMPR and DPM also inhibit the release of adenosine from cells. In the present study, these results cannot be attributed to such an effect. Modification of the binding characteristics of adenosine by nucleoside transport inhibitors may be involved, but there is no evidence at present to suggest this consideration may be important. In any case, the response to adenosine correlated well with its uptake, irrespective of the nucleoside blocker used. It is unlikely that any diverse characteristics should result in the same electrophysiological effect which we attribute to a known common action on adenosine transport.
Diazepam is a potent inhibitor of adenosine uptake in brain slices (Mah and Daly, 1976) and has also been shown to potentiate the negative inotropic action of adenosine in guinea pig atria (Clanachan and Marshall, 1980) . In this latter study, it was suggested that uptake inhibition was the most likely mechanism for the potentiation of adenosine by DIAZ. As suggested by Clanachan and Marshall (1979) , the coronary vasodilator action of DIAZ observed in dogs (Abel et al., 1970) and humans (Ikram et al., 1973) could be explained by its ability to inhibit adenosine uptake. Clinical concentrations of DIAZ are on the order of 10" 6 to 10~5 M (Hillestad et al., 1974) and, hence, in the range in which inhibition of adenosine uptake was presently observed. However, it remains to be determined whether the inhibition of myocardial uptake of adenosine has any role in cardiovascular actions of DIAZ other than the electrophysiological effects reported in our study. Drury and Szent-Gyorgi (1929) were probably the first investigators to report that the effects of adenosine were inversely related to temperature. In our previous work (Belardinelli et al., 1980) , it was also reported that the prolongation of the A-H interval and the AV block caused by adenosine were influenced by the temperature of the perfusate. At 34°C, the concentration of adenosine required to cause a given prolongation in the A-H interval was lower than at 37°C. That is, at 37°C, the adenosine dose-response curve was shifted to the right. As illustrated in Figure  1 , at 32°C, a small reduction in adenosine uptake occurred. In guinea pig and rat hearts, the uptake of adenosine has been found to be temperature dependent (Hopkins and Goldie, 1971) . This finding may explain the apparent increased sensitivity to adenosine at lower temperatures.
Recently, adenosine was proposed to modulate membrane-bound adenylate cyclase at two distinct sites, designated as R and P sites (Wolff et al., 1981) .
The R site, presumably located on the external surface of the cell membrane, is thought to accept adenosine and its purine-modified derivatives, whereas the P site, which has been localized on the cytoplasmic surface of the membrane, accepts adenosine and its ribose-modified analogues. Whereas binding to the R site induced either activation or inhibition of the adenylate cyclase, binding to the P site caused only inhibition. The lack of effect of the P site analog 2'-deoxyadenosine as opposed to the effect of the R site analog N 6 -methyladenosine suggests that the adenosine-induced A-H prolongation is mediated via the R site.
The oligonucleotide, adenyI-(3'-5')9-adenosine has a molecular weight of about 3,300 and is too large to enter the intact cell. Hartzell (1979) showed that, on a molar basis, this oligonucleotide was about 2.6-fold more potent than free adenosine in producing hyperpolarization in frog sinus venosus cells. Such a finding was considered as evidence in favor of the presence of adenosine receptors on the surface of sinus myocytes. The same macromolecule was also used to reach a similar conclusion concerning the reduction of oxygen uptake in frog sartorius muscle produced by adenosine (Prosdocimi and Bianchi, 1981) . In our preparation, the polymer (AP)9-adenosine was approximately 1.8 times more potent per mole than adenosine in producing prolongation of the A-H interval. Thus, since this molecule is impermeable to the cell membrane because of its large size, these data indicate that, in the AV nodal cells, the adenosine receptor responsible for the prolongation of AV conduction time is located on the external surface of the membrane.
Based on the finding that three different nucleoside transport inhibitors potentiate the actions of adenosine, and that the adenosine polymer (AP)9-A mimics the effects of adenosine, it is reasonable to suggest that the adenosine-induced A-H prolongation is mediated by an extracellular receptor site. Further, since the N 6 -methyladenosine mimicked the action of adenosine, whereas the 2'-deoxyadenosine was ineffective, it seems likely that adenosine is acting in the AV node by binding to a receptor that resembles the R site described for other actions of adenosine in different tissues.
Antagonism between Adenosine and Aminophylline
It has long been recognized that methylxanthines can inhibit cyclic AMP phosphodiesterase activity (Sutherland and Rail, 1958) . Relatively high concentrations are required to achieve this. The concentration of theophylline required for phosphodiesterase inhibition is in excess of 2 X 10~4 M (Butcher and Sutherland, 1962) . Kukovetz et al. (1975) reported that 1.8 X 10~3 M aminophylline and 2 X 10~3 M theophylline were required for half-maximal inhibition of phosphodiesterase from guinea pig hearts. It was also shown that in the isolated perfused guinea pig heart,mum inotropic response, produced a 55 ± 17% inhibition of phosphodiesterase. The present observation that aminophylline at 1 X 10~4 M did not increase cyclic AMP but did so at 1 X 1CT 2 M is consistent with previous reports (Butcher and Sutherland, 1962; Kukovetz et al., 1975) . Thus, the aminophylline reversal of adenosine-induced A-H prolongation and AV block cannot be explained by possible inhibition of phosphodiesterase activity.
Methylxanthines are known to stimulate the release of catecholamines from the adrenal medulla (Peach, 1972; Poisner, 1973) and from adrenergic nerve endings (Westfall and Fleming, 1968; Westfall and Brasted, 1974; Hedqvist et al., 1978) . The lowest concentration of theophylline used to stimulate catecholamine release from the adrenal gland was 5 X 10~4 M, but in general, concentrations above 1 ITIM were used (Peach, 1972; Poisner, 1973) . Furthermore, the theophylline-stimulated release of catecholamines was short lived even though theophylline was continuously present in the perfusate (Peach, 1972) . With respect to the myocardium, early evidence that methylxanthines stimulate the release of catecholamines was largely indirect (Westfall and Fleming, 1968; Marcus et al., 1972) . However, in a later study of the specificity of blockade of nicotine-induced release of 3 H-norepinephrine, aminophylline (5 X 10~3 M) was one of the agents utilized to provoke the release of 3 H-norepinephrine from guinea pig heart (Westfall and Brasted, 1974) . In another study utilizing the perfused rabbit kidney, infusion of theophylline (10" (> to 10~4 M) had no effect on the spontaneous release of 3 H-norepinephrine, whereas at 1CT 5 to 10~4 M, theophylline caused a small, but significant, increase in the 3 H-norepinephrine release induced by nerve stimulation (Hedqvist et al., 1978) . In our preparation, 3 X 10~5 to 5 X 10~5 M aminophylline did not increase the spontaneous release of norepinephrine. A small, but not significant, increase in norepinephrine release was observed at 10~4 M aminophylline, and a significant (2.5-fold) increase was noted at 1CT 2 M aminophylline. Therefore, with regard to adenosine-induced AV conduction delay, the effects of aminophylline at concentrations lower than 10~4 M cannot be attributed to release of catecholamines. This is supported by the observation that 3 X 10~5 M aminophylline antagonized over 95% of the prolongation of the A-H interval caused by 7 X 10~6 M adenosine (Fig. 8) without resulting in any release of norepinephrine and/or accumulation of cyclic AMP (Figs. 10 and 11) . Furthermore, aminophylline reverses the effects of adenosine in propranolol-treated hearts. However, since the release of catecholamines from the adrenal medulla induced by theophylline may occur at concentrations below 1CT 4 M, the role of catecholamines as mediators of methylxanthine actions in vivo preparations cannot be dismissed.
Our finding of a common ordinate intersect in Figure 9 is also consistent with the suggestion that the effects of adenosine are competitively inhibited by theophylline and aminophylline (Biinger et al., 1975; Dutta and Mustafa, 1979; Hartzell, 1979) . This interpretation is also supported by the observation that aminophylline does not affect adenosine uptake and/ or release from cardiac cells (Mustafa et al., 1975) . Further evidence that this antagonism between adenosine and theophylline is at an extracellular site can be found in the report of Olsson et al., (1976) . It was shown that the coronary vascular effects of adenosine and theophylline covalently linked to oxidized stachyose, i.e., derivatives too large to penetrate the coronary smooth muscle cells, were antagonistic (Olsson et al., 1976) .
The selectivity of the antagonism between adenosine and aminophylline on the AV node is supported by the previous observation that when AV conduction is impaired by several different substances (i.e., Ach, MnCl2, adenosine) only the AV conduction delay caused by adenosine was reversed by aminophylline (Belardinelli et al., 1980) . Although indirect, all the above-mentioned observations indicate that the antagonism between adenosine and aminophylline is selective and most likely at the level of an external membrane site.
In conclusion, the physiological significance of adenosine receptors, especially in the heart, is still unknown; however, the results described here indicate a more widespread occurrence of such receptors than previosuly recognized. In addition, we have demonstrated that under specific conditions, the reversal of adenosine-induced AV conduction delay by aminophylline is not due to inhibition of phosphodiesterase activity or the release of catecholamines from nerve terminals. As previously postulated for other systems (Rail, 1981) , it is suggested that the blockade of adenosine receptors is the most suitable explanation for the ability of aminophylline to reverse the negative dromotropic effects of adenosine.
